Iovance Biotherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Iovance Biotherapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About IOVA
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors.
CEOFrederick G. Vogt
CEOFrederick G. Vogt
Employees838
Employees838
HeadquartersSan Carlos, California
HeadquartersSan Carlos, California
Founded2007
Founded2007
Employees838
Employees838
IOVA Key Statistics
Market cap1.17B
Market cap1.17B
Price-Earnings ratio-2.74
Price-Earnings ratio-2.74
Dividend yield—
Dividend yield—
Average volume8.34M
Average volume8.34M
High today$3.66
High today$3.66
Low today$3.54
Low today$3.54
Open price$3.65
Open price$3.65
Volume6.27M
Volume6.27M
52 Week high$14.23
52 Week high$14.23
52 Week low$2.70
52 Week low$2.70
Analyst ratings
92%
of 13 ratingsBuy
92.3%
Hold
7.7%
Sell
0%
People also own
Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.